Head to Head Contrast: Beigene (ONC) vs. The Competition

Beigene (NASDAQ:ONC) is one of 1,075 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Beigene to similar businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Valuation & Earnings

This table compares Beigene and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Beigene	$3.81 billion	-$881.71 million	-39.89
Beigene Competitors	$9.89 billion	$136.37 million	-5.89

Beigene’s peers have higher revenue and earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

48.5% of Beigene shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 6.6% of Beigene shares are owned by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Beigene and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beigene	0	0	5	0	3.00
Beigene Competitors	8547	22459	50647	1373	2.54

Beigene currently has a consensus price target of $318.88, indicating a potential upside of 30.21%. As a group, “Pharmaceutical preparations” companies have a potential upside of 222.84%. Given Beigene’s peers higher probable upside, analysts plainly believe Beigene has less favorable growth aspects than its peers.

Profitability

This table compares Beigene and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beigene	-25.94%	-25.12%	-14.95%
Beigene Competitors	-3,399.87%	-235.11%	-32.77%

Volatility & Risk

Beigene has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Beigene’s peers have a beta of 3.84, indicating that their average share price is 284% more volatile than the S&P 500.

Summary

Beigene peers beat Beigene on 7 of the 13 factors compared.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.